ReviewCell and tissue research2026
Connexin-Pannexin duality in glioblastoma.
Review in Cell and tissue research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- From channels to communication networks: a perspective on connexins, pannexins and innexins.Cell and tissue research · 2026Article
- Actin, connexin-43 and GAP-43 expression in gliomas: real-world associations with IDH status, tumor burden and survival.Journal of neuro-oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Glioblastoma (GBM) is the most aggressive primary brain tumour in adults, characterized by extensive heterogeneity and diffuse invasion. Increasing evidence highlights the role of channel-forming proteins in glioma biology. Connexins (Cxs) and Pannexins (Panxs) are two structurally related yet functionally distinct protein families that mediate cellular communication. While both regulate overlapping processes such as ion homeostasis and ATP release, only Cxs are capable of readily forming intercellular gap junctions. Cx43 is the most extensively studied connexin in GBM and seems to display paradoxical roles, acting as a tumour suppressor by reducing proliferation while promoting invasion. In contrast, Panx1 predominantly supports tumour progression, while Panx2 exerts tumour-suppressive effects. This review synthesizes how Cxs and Panxs exert context-dependent and sometimes opposing effects across stages of GBM, including proliferation and invasion, and examines how divergent experimental models may contribute to apparent contradictions. Discrepancies among studies often arise from differences in model systems, which may not recapitulate the complexity of human GBM. Given the profound heterogeneity of this tumour, future research should prioritize patient-derived and three-dimensional models that more accurately represent the human disease context. Such approaches will be essential to clarify the context-dependent functions of Cxs and Panxs and their potential as therapeutic targets in GBM.
Indexed as
Identifiers
41543596What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.